EDITORIAL

Theophylline and phosphodiesterase Inhibitors

M. Aubier*, P.J. Barnes**

This issue of the European Respiratory Journal starts a series of short reviews based on a Satellite Meeting held during the European Respiratory Society Annual Meeting in Nice in October 1994. The symposium was supported by Byk Gulden (Germany) and brought together experts who discussed new data on the immunomodulatory action of theophylline, and also looked at future developments with more selective phosphodiesterase (PDE) inhibitors.

Theophylline has been used for more than 50 yrs in the treatment of asthma. The proposed clinical effects of theophylline are bronchial smooth muscle relaxation, improved mucociliary clearance, increased efficiency of diaphragmatic contraction, decreased pulmonary artery pressure, and central respiratory stimulation. It is now increasingly recognized that, besides these classical clinical properties, theophylline and more selective PDE inhibitors have anti-inflammatory and immunomodulatory effects. Indeed several studies have demonstrated that, in vitro, xanthines have a nonspecific suppressor activity in human peripheral lymphocytes [1], inhibit eosinophil degranulation [2], inhibit histamine release from mast cells and basophils [3], and have a direct inhibitory action on human alveolar respiratory burst [4]. These anti-inflammatory and immunomodulatory effects of xanthines have also been observed in vivo in animal models and also in humans. In the guinea-pig, it has been shown that xanthines attenuate airway hyperresponsiveness [5] and the late response in sensitized animals [6]. They also inhibit eosinophil infiltration into guinea-pig airways [7].

In humans, xanthines also inhibit the late asthmatic response [8], and reduce neutrophil and eosinophil activation in airways, to an extent comparable to the effect of low dose inhaled steroids (0.4 mg budesonide daily) [9]. Finally, theophylline withdrawal causes a worsening of clinical asthma, even in patients already receiving high dose inhaled steroids [10, 11]. This is associated with a fall in activated T-lymphocytes in the blood, and a rise in these cells in the airway mucosa, suggesting that theophylline may regulate the trafficking of activated lymphocytes into the airways. The target cell for theophylline action may, therefore, be either T-cells or bronchial vascular endothelial cells that regulate lymphocyte migration [11].

Interestingly, in some studies, these anti-inflammatory and immunomodulatory effects of theophylline have been observed at rather lower plasma concentrations than those considered to be required for bronchodilatation. This has suggested that theophylline might be used for the maintenance treatment of asthma at lower doses, rather than aiming for plasma concentrations of 10–20 mg·l⁻¹ that were determined as a compromise between the bronchodilatory effect of theophylline and side-effects. It may be more useful to aim for plasma concentrations of 5–10 mg·l⁻¹, as this would preserve the immunomodulatory effect but avoid the side-effects that limit its usefulness [12].

Although theophylline is known to be a nonselective inhibitor of PDEs, it is not certain whether its anti-asthma actions can be entirely explained by this mechanism. The therapeutic plasma concentrations of theophylline are in the range 25–100 µM, when there is relatively little inhibition of PDE activity. At present, there is no evidence of selectivity of theophylline for any of the PDE iso-enzyme families, although it remains a possibility that unique PDE iso-enzymes may be discovered that are more sensitive to theophylline. It is also possible that certain PDE iso-enzymes are induced in asthmatic airways, and this may increase the sensitivity of asthmatic cells to inhibition by theophylline. Whilst some of the actions of theophylline may be due to PDE inhibition, it is likely that there are other molecular mechanisms of action, and this area deserves further study. Nevertheless, the interest in PDEs prompted by the pharmacology of theophylline has led to an enormous interest in PDE iso-enzymes, and much new information about PDE iso-enzymes in the airways is discussed in this series of reviews. This will undoubtedly result in new therapeutic agents for the treatment of asthma in the future, particularly if the problem of side-effects can be overcome.

Theophylline remains a very useful treatment for asthma, particularly in patients with severe disease. The demonstration that it may have immunomodulatory or anti-inflammatory effects, even at low plasma concentrations, has posed the question of how theophylline should be placed in the guidelines for asthma treatment in the future. At present, most guidelines recommend that theophylline is added after high dose inhaled steroids (1.5–2 mg daily). It is probable that theophylline exerts its anti-asthma effects via different molecular mechanisms from glucocorticoids, and there are theoretical reasons to believe that there may be a synergistic interaction between these two classes of drug. The
steroid-sparing effects of theophylline have long been recognized [13], and recent studies have documented that theophylline gives comparable control of asthma to an inhaled glucocorticoid (beclomethasone dipropionate, 0.4 mg daily) in children with mild to moderate asthma [14]. This suggests that theophylline may be used in combination with inhaled steroids to control asthma, without the need to increase the dose of inhaled steroids when symptoms are not controlled at doses of 0.4–0.8 mg daily. Controlled trials are currently in progress to explore this possibility. The fact that theophylline is active orally and may be given once or twice daily may help to increase compliance [15]. In the future, it is possible that theophylline will be introduced even earlier in management, at a stage which precedes the use of inhaled steroids, but carefully controlled clinical trials will be needed before this can be recommended.

In response to the new information about theophylline that is discussed in detail in this series of reviews, its role in the management of asthma should now be re-evaluated. Future clinical studies in chronic asthma are required to evaluate the anti-inflammatory and immuno-modulatory effects of more selective PDE inhibitors, particularly PDE IV inhibitors, to determine whether the encouraging in vitro and in vivo animal studies can be extrapolated to the clinical situation.

References


